Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) EBIT Margin: 2020-2025

Historic EBIT Margin for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to -4,249.23%.

  • Insight Molecular Diagnostics' EBIT Margin rose 750294.00% to -4,249.23% in Q3 2025 from the same period last year, while for Sep 2025 it was -1,392.91%, marking a year-over-year increase of 475561.00%. This contributed to the annual value of -3,245.14% for FY2024, which is 157275.00% down from last year.
  • According to the latest figures from Q3 2025, Insight Molecular Diagnostics' EBIT Margin is -4,249.23%, which was down 123.64% from -1,900.00% recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' EBIT Margin ranged from a high of 1,969.70% in Q1 2023 and a low of -11,752.17% during Q3 2024.
  • Moreover, its 3-year median value for EBIT Margin was -2,262.92% (2024), whereas its average is -3,335.81%.
  • As far as peak fluctuations go, Insight Molecular Diagnostics' EBIT Margin spiked by 5,168,307bps in 2021, and later plummeted by 1,023,399bps in 2024.
  • Over the past 5 years, Insight Molecular Diagnostics' EBIT Margin (Quarterly) stood at -994.15% in 2021, then plummeted by 325,695bps to -4,251.09% in 2022, then slumped by 90,145bps to -5,152.55% in 2023, then spiked by 288,963bps to -2,262.92% in 2024, then spiked by 750,294bps to -4,249.23% in 2025.
  • Its last three reported values are -4,249.23% in Q3 2025, -1,900.00% for Q2 2025, and -318.01% during Q1 2025.